China's anti-cancer drug research attracts international attention
January 11, 2019 Source: Science and Technology Daily
Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];Recently, the National Cancer Center and the Chinese Academy of Medical Sciences Cancer Hospital Professor Shi Yuankai led the domestic PD-1 monoclonal antibody treatment of relapsed or refractory classic Hodgkin's lymphoma, and the international authoritative journal "Lancet blood disease" The first cover of the 2019 issue.
According to Xinhua News Agency, Hodgkin's lymphoma is a rare B-cell malignant lymphoma, which occurs mostly in young people between the ages of 20 and 40, most of which are classic. Despite its early treatment and high cure rate, about 20% of first-line treatments have developed into relapsed or refractory classic Hodgkin's lymphoma, and there is no effective treatment for such patients.
Shi Yuankai led the study to include 96 patients. It is the most relapsed or refractory classic Hodgkin's lymphoma study in China. The single-agent is based on the self-developed class 1 innovative drug, EDLI monoclonal antibody. treatment. The results of the study showed that the objective response rate was 80.4%, and the curative effect was comparable to that of imported similar drugs, and the safety was good.
It is understood that, in normal terms, T lymphocytes in the human immune system are like "police", which can identify and eliminate mutant cells in the body in time to prevent tumors. However, the tumor microenvironment can lead to the inhibition of T lymphocyte function, which can not kill tumor cells, which is one of the reasons why the tumor is inadvertently developed and difficult to be overcome.
Experts say that unlike traditional chemotherapy and targeted therapy, PD-1 monoclonal antibody can reactivate and restore the patient's own immune cells to kill tumors by overcoming the immunosuppression in patients. PD-1 monoclonal antibody has thus become a hot topic in the current cancer immunotherapy, with broad-spectrum, relatively long-lasting efficacy and lesser side effects than traditional chemotherapy.
In December 2018, the first domestic PD-1 monoclonal antibody, Treipril monoclonal antibody injection and Xindeli monoclonal antibody injection, was approved. Shi Yuankai said: "The approval of the domestic PD-1 monoclonal antibody will bring more treatment options for cancer patients in China."
Raw Material For Surgical Drape And Gown
Non Woven,Non Woven Fabric,Non Woven Material,Non Woven Fabric Roll
ShaoXing SurgeCare Medical Products Co., Ltd. , https://www.sxsurgecaremedical.com